Actual enrollment increased by 87 participants
Before: 141 participants (actual). After: 228 participants (actual).
Study sponsor: VistaGen Therapeutics, Inc. · VTGN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Before: 141 participants (actual). After: 228 participants (actual).